Afucosylated monoclonal antibody
AssigneesBeijing Gefucure Biotechnology Limited Company, Wuxi Kingenew Biotechnology Limited Company
InventorsBo Tang, Ran Zhang, Jianmin Zhao, Jianwu Wang, Yunping Dai
Life of this patent
Estimating the term…
Abstract
Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a composition containing the monoclonal antibody. Compared with a fucosylated monoclonal antibody, the provided afucosylated monoclonal antibody has higher biological activity in vitro and in vivo and can be used for developing more effective therapeutic monoclonal antibody drugs.
Claims5
An afucosylated monoclonal antibody, wherein
- the afucosylated monoclonal antibody is a human IgG anti-CD20 antibody, and the glycoform core structure of the afucosylated monoclonal antibody is mainly afucosylated glycoform;
- the afucosylated glycoform accounts for 80% to 100% of the glycoform core structure of the monoclonal antibody;
- the glycoform has a G2 glycoform core structure that accounts for 30% to 100% of the afucosylated glycoform;
- the G2 glycoform means that the glycoform core structure of the antibody does not contain a fucose group, and the terminal of the sugar chain has two galactose groups;
- the glycoform core structure of the G2 glycoform monoclonal antibody is a sugar chain structure represented by the following formula (I):
- and
- the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:
- 1, and the light chain comprises the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.